Dr. Appel is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
6560 Fannin St
Ste 802
Houston, TX 77030Phone+1 713-441-3760Fax+1 713-793-7271
Education & Training
- University of Pennsylvania Health SystemResidency, Neurology, 1965 - 1966
- Icahn School of Medicine at Mount Sinai/Mount Sinai HospitalResidency, Neurology, 1961 - 1962
- Massachusetts General HospitalInternship, Internal Medicine, 1960 - 1961
- Columbia University Vagelos College of Physicians and SurgeonsClass of 1960
Certifications & Licensure
- TX State Medical License 1977 - 2025
- NC State Medical License 1967 - 1982
- American Board of Psychiatry and Neurology Neurology
Awards, Honors, & Recognition
- Investigator Alumnus Howard Hughes Medical Institute, 1976
- Elected Member The American Society for Clinical Investigation, 1969
- Super Doctor SuperDoctors.com
- Join now to see all
Clinical Trials
- Genomic Translation for Amyotrophic Lateral Sclerosis Care Start of enrollment: 2016 Jun 08
- T-regulatory Cells in ALS Start of enrollment: 2019 Aug 07
Publications & Presentations
PubMed
- Barriers to Tofersen Therapy for Variant SOD1-Mediated ALS.Stanley H Appel, Jason R Thonhoff
JAMA Neurology. 2024-12-01 - Safety and tolerability of tegoprubart in patients with amyotrophic lateral sclerosis: A Phase 2A clinical trial.Steven Perrin, Shafeeq Ladha, Nicholas Maragakis, Michael H Rivner, Jonathan Katz
Plos Medicine. 2024-10-01 - 1 citationsPrimary visual cortex pathology in ALS patients with C9ORF72 expansion.Matthew D Cykowski, Anithachristy S Arumanayagam, Suzanne Z Powell, Stanley H Appel
Brain Pathology. 2024-09-01
Press Mentions
- Energy Co. Makes $100,000 Donation to Houston HospitalSeptember 4th, 2024
- Coya Therapeutics Reports Data from Alzheimer’s Disease Therapy TrialApril 3rd, 2023
- Alzheimer’s Diagnoses Expected to Reach Nearly 13 Million by 2050, Says New ReportMarch 17th, 2023
- Join now to see all
Grant Support
- Clinical Trial: Phase I/II Trial Using Cyclophosphamide And Low-Dose IL-2 To InNational Center For Research Resources2011
- Using CD4+ T Cells As A Candidate Therapy To Slow Disease Progression In ALSNational Institute Of Neurological Disorders And Stroke2010–2011
- Clinical Trial: Phase I/II Trial Using Cyclophosphamide And Low-Dose IL-2 To INDNational Center For Research Resources2010
- The Role Of Microglia In Models Of ALSNational Institute Of Neurological Disorders And Stroke2005–2007
- The Role Of Microglia In Models Of ALSNational Institute Of Neurological Disorders And Stroke2004
- Selective Vulnerability Of Sporadic Neurodegenerative DiseaseNational Institute On Aging1997–2000
- Alzheimers Disease Research CenterNational Institute On Aging1994–2000
- ALS IGG Effects On Motorneuron UntrastructureFogarty International Center1996–1998
- Selective Neuronal Vulnerability In Sporadic ALSNational Institute Of Neurological Disorders And Stroke1994–1997
- Alzheimer'S Disease Research CenterNational Institute On Aging1989–1993
- NeurosciencesNational Institute Of Neurological Disorders And Stroke1988
- Neurosciences Training ProgramNational Institute Of Neurological Disorders And Stroke1985–1987
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: